Quick Facts

• Goal: To help manage high blood pressure (hypertension).
• Goal: Used in the management of symptomatic heart failure.
• Goal: May help reduce the progression of asymptomatic left ventricular dysfunction.

---

Enap is a therapeutic option used to address several cardiovascular conditions. Its primary use is in the management of high blood pressure (hypertension). Maintaining blood pressure within a healthy range is important to help reduce the risk of serious cardiovascular events such as stroke and myocardial infarction.

Additionally, Enap is used to help manage symptomatic heart failure. In this context, it is often utilized alongside other medications, such as diuretics and digitalis, to help improve outcomes and decrease the frequency of hospitalization related to the condition. Treatment with Enap may contribute to increased survival in patients with heart failure.

The medication is also indicated for use in clinically stable patients who have asymptomatic left ventricular dysfunction (defined as an ejection fraction of 35% or less). In this patient population, its use may help decrease the rate at which overt heart failure develops and help reduce the incidence of hospitalization.

Eligibility and Contraindications for Enap (Enalapril)

Official regulatory documents define strict criteria for the use of Enap, an Angiotensin-Converting Enzyme (ACE) inhibitor.

Populations that Must Not Use Enap (Contraindications):

• Prior Angioedema: Patients with a history of swelling of the face, lips, tongue, or throat (angioedema) related to previous use of any ACE inhibitor must not use this medicine.
• Hereditary/Idiopathic Angioedema: Patients diagnosed with hereditary or angioedema of unknown cause (idiopathic) are strictly excluded.
• Pregnancy: Use is contraindicated during the second and third trimesters of pregnancy due to the high risk of severe fetal injury or death. Use is generally not recommended during the first trimester.
• Drug Interactions: Use is contraindicated in patients with diabetes who are also taking the direct renin inhibitor aliskiren. It is also contraindicated for use within 36 hours of taking a medicine containing a neprilysin inhibitor (e.g., sacubitril).

Populations with Restricted or Cautious Use:

• Pediatric Use: Use is established in children aged 1 month to 16 years for certain conditions, but it is not recommended for infants le 1 month of age or in children with severe kidney impairment (Glomerular Filtration Rate <30 mL/min/1.73 m^2).
• Renal Impairment: Dosing requires adjustment in patients with severe kidney impairment.
• Lactation: Use is not recommended for women who are breastfeeding.

Interactions with other medicines and products

Official regulatory documents define specific drug interaction constraints for Enalapril (marketed as Enap), primarily related to two main safety risks: hyperkalemia (elevated potassium) and angioedema (severe swelling).

Contraindicated Combinations and Timing Rules

Interacting Product Category	Constraint (Severity)	Practical Requirement
Neprilysin Inhibitors (e.g., Sacubitril)	Contraindicated	Must not be used within 36 hours of discontinuing Enalapril, and vice versa.
Aliskiren	Contraindicated	Must not be used in patients with diabetes mellitus or moderate-to-severe renal impairment.

Clinically Significant Interactions

Interactions that may require close patient monitoring or modification of therapy include the use of:

• Potassium-Sparing Agents: The combination with potassium-sparing diuretics (e.g., Amiloride, Triamterene) or Potassium Supplements may lead to elevated serum potassium levels and requires caution.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use with NSAIDs (e.g., ibuprofen, high-dose aspirin) may diminish the blood pressure-lowering effect and increase the risk of deterioration in kidney function, especially in elderly or volume-depleted individuals.
• Lithium: The co-administration of Lithium and Enalapril may increase the concentration of Lithium in the blood, which may lead to potential toxicity.
• Other Antihypertensives: Co-administration with other blood pressure-lowering agents, including diuretics, may result in a greater risk of significant low blood pressure (hypotension).

The official labeling emphasizes the necessity of avoiding dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) where possible, detailing specific patient conditions under which certain combinations are prohibited.

Enap, a prodrug, undergoes hepatic hydrolysis via carboxylesterase 1 (CES1) to yield its pharmacologically active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase.

ACE is the biological target responsible for catalyzing the cleavage of angiotensin I to form the potent vasoconstrictor, angiotensin II, within the Renin-Angiotensin-Aldosterone System (RAAS). By inhibiting ACE, enalaprilat decreases the systemic and local concentrations of angiotensin II. This reduction in angiotensin II leads to a diminished stimulation of the angiotensin II type 1 (AT1) receptors located on vascular smooth muscle cells, resulting in vasodilation and a subsequent reduction in systemic vascular resistance. Simultaneously, the decrease in angiotensin II reduces the stimulation of the adrenal cortex, leading to decreased secretion of aldosterone. This downstream cascade modulates renal fluid and electrolyte balance by promoting natriuresis (sodium excretion) and water loss, ultimately resulting in a reduction in total plasma volume. Additionally, ACE is identical to kininase II, which degrades the vasodepressor peptide bradykinin. Inhibition of ACE therefore impedes the breakdown of bradykinin, leading to elevated local levels of the peptide, which may contribute an additional component of vasodilation.

Official Administration Guidelines

The usage of Enap (Enalapril maleate) is defined by official instructions regarding the route, dosing schedule, and required administration conditions, ensuring a standardized procedural approach.

Instruction Category	Official Guideline
Routes and Forms	Primarily Oral (tablet, 2.5 mg to 20 mg strengths). The active compound, Enalaprilat, is administered Intravenously (IV) in acute scenarios.
Timing in Relation to Meals	Oral Enalapril may be taken with or without food, as absorption is not significantly affected by meal consumption.
Missed-Dose Rules	If a scheduled dose is missed, it should be taken as soon as it is remembered. If it is nearly time for the next dose, the patient should skip the missed dose and resume the normal schedule.
Special Procedural Conditions	The initiation of therapy for symptomatic heart failure or in patients currently using diuretics necessitates close medical observation following the first dose.

---

Dosing Schedule and Adjustments

The standard approach involves a titratable dosing schedule that progresses from an initial low dose to a long-term maintenance dose. For Hypertension, the starting dose is often 5 mg once daily, progressing toward a maximum of 40 mg per day. For Heart Failure, the initial dose is 2.5 mg once or twice daily, which is then gradually adjusted over a period of several weeks.

Population-Specific Adjustments

Dose modifications are required for specific patient populations. Patients with Renal Impairment (creatinine clearance le 30 mL/min) must begin therapy with a reduced starting dose of 2.5 mg once daily. Dosage for pediatric patients with hypertension is determined using a weight-based formula, starting at 0.08 mg/kg once daily.

The efficacy of Enalapril (Enap) is supported by a substantial body of clinical research, including large-scale, long-term studies that established its role as an angiotensin-converting enzyme (ACE) inhibitor for several cardiovascular conditions.

Core Indications: Evidence Overview

• Chronic Hypertension: Clinical trials consistently demonstrate that Enalapril may reduce both systolic and diastolic blood pressure. Its blood pressure-lowering effect is generally maintained with continued daily administration, helping to mitigate the risk of adverse cardiovascular events.
• Heart Failure (Reduced Ejection Fraction): Enalapril is associated with a decrease in the rate of hospitalization and all-cause mortality in individuals diagnosed with heart failure and reduced ejection fraction (HFrEF). Research suggests that its benefits may be observed across various doses, even those below the target dose used in major clinical trials like SOLVD (Studies of Left Ventricular Dysfunction).
• Asymptomatic Left Ventricular Dysfunction (LVD): Studies indicate that Enalapril may delay the progression from asymptomatic LVD to symptomatic heart failure, suggesting a protective role for the heart muscle in this population.

Renal and Cardiovascular Health

In addition to its primary indications, evidence suggests Enalapril may play a role in renal protection, particularly in slowing the decline of kidney function in patients with chronic kidney disease, especially those with hypertension or diabetes. Other research has explored its effects on endothelial function and arterial stiffness, demonstrating sustained benefits on these cardiovascular risk factors in certain populations.

Common questions about Enap (FAQ)

Q: How long does it take for Enap to start working after I take the first dose?

According to official product information, Enap (Enalapril) begins to lower blood pressure within approximately one hour of taking an oral dose. The maximum blood pressure-lowering effect, or peak effect, is typically observed to occur between four and six hours after the dose. This peak time frame reflects when the medication’s effect is generally at its maximum.

---

Q: What is the standard dose of Enap for a child with high blood pressure?

Official information regarding pediatric use generally applies to children aged 6 to 16 years with hypertension. For this group, the dose is usually calculated based on the child’s weight, often starting at 0.08 mg/kg once daily. Dosage titration, or adjustment, is performed by the healthcare provider based on the child's response to the initial dose.

---

Q: What is the half-life of Enalapril?

The half-life refers to the time it takes for half of the drug to be cleared from the body. Enap is a prodrug, which means it is converted into its active form, Enalaprilat. Regulatory documents state that Enalaprilat has an effective accumulation half-life of approximately 11 hours when the medication is taken multiple times. The half-life is a measurement used in pharmacokinetics to understand how the drug is processed by the body.

---

Q: Can I use alcohol while taking Enap?

Official drug safety information indicates that concurrent use of alcohol with Enalapril is generally not recommended. This is because alcohol may increase the blood pressure-lowering effects of the medication. Combining them may increase the risk of side effects like dizziness, lightheadedness, or fainting.

---

Q: How can I get rid of unused or expired Enap medicine safely?

To dispose of expired or unused Enap, regulatory documents emphasize the need to comply with federal, state, and local regulations. Patients are generally advised to look for and utilize official drug take-back programs available in their area. Disposal should be done according to authorized pharmaceutical waste procedures, and placing it in household trash or wastewater is generally avoided.

How to Store and Dispose of Enap

Enalapril maleate tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is essential to keep the medicine in its original container and ensure the container remains tightly closed to protect the tablets from moisture and direct light.

Do not freeze Enap, and avoid storing it in areas exposed to excessive heat.

For safety, the medication must be stored out of the reach and sight of children.

Disposal of expired or unused Enap must be conducted in accordance with Federal, State, and Local regulations. The product should not be disposed of in wastewater, and official drug take-back programs or authorized pharmaceutical waste procedures should be utilized.